Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02435992 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis
A Phase 3 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,012
- Enrollment target
NCT02435992 is a Phase 3 study that has completed, run by Celgene. The registered enrollment target is 1,012 participants.
The verdict
NCT02435992, a Phase 3 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,012 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether RPC1063 is effective in the treatment of Ulcerative Colitis (UC).
Interventions
- DRUG Placebo
- DRUG RPC1063
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,012 participants |
| Start Date | 2015-06-17 |
| Est. Completion | 2020-06-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02435992
The ClinicalTrials.gov registry entry for NCT02435992 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,012 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02435992 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02435992 about?
NCT02435992 is a clinical study titled "Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis". The purpose of this study is to determine whether RPC1063 is effective in the treatment of Ulcerative Colitis (UC).
What is the current status of trial NCT02435992?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,012 participants. The study started on 2015-06-17. Estimated completion is 2020-06-17.
What interventions are being tested in trial NCT02435992?
The interventions under investigation include: Placebo (DRUG), RPC1063 (DRUG).
Who is sponsoring clinical trial NCT02435992?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.